💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Simeprevir

CHEMBL501849 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
749.9 g/mol
LogP
4.8
Phase
4

Simeprevir is a macrocyclic peptidomimetic inhibitor of the hepatitis C virus NS3/4A serine protease, used for the treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infection in combination with other antiviral agents. By competitively binding the NS3/4A protease active site, it blocks viral polyprotein processing and inhibits HCV replication. It achieves high sustained virologic response rates when combined with sofosbuvir or pegylated interferon plus ribavirin.

น้ำหนักโมเลกุล

749.9000 g/mol

LogP

4.80

TPSA

194.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

HIV/AIDS Hepatitis C Tuberculosis

กลไกการออกฤทธิ์

Inhibits the NS3/4A serine protease of hepatitis C virus, blocking the processing of the viral polyprotein essential for replication.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Inhibits the NS3/4A serine protease of hepatitis C virus, blocking the processing of the viral polyprotein essential for replication.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C

                

                

                
                

                    
InChI

                    
InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C38H47N5O7S2

                    

                    
                    

                        
HBD / HBA

                        
2 / 10

                    

                    
                    

                        
พันธะที่หมุนได้

                        
8

                    

                    
                    
                    

                        
อะตอมหนัก

                        
52

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
Simeprevir is a macrocyclic peptidomimetic inhibitor of the hepatitis C virus NS3/4A serine protease, used for the treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infection in combination with other antiviral agents. By competitively binding the NS3/4A protease active site, it blocks viral polyprotein processing and inhibits HCV replication. It achieves high sustained virologic response rates when combined with sofosbuvir or pegylated interferon plus ribavirin.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits the NS3/4A serine protease of hepatitis C virus, blocking the processing of the viral polyprotein essential for replication.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Simeprevir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL501849.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 24873435.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.